Issue Date: March 13, 2017
Boehringer, Vanderbilt pact targets KRAS
Advancing a two-year-old cancer drug discovery partnership, Boehringer Ingelheim and Vanderbilt University will research and develop small molecules targeting a protein called SOS that acts as a molecular switch activating KRAS, a gene essential to normal tissue signaling. Mutations of the gene are responsible for the onset of various forms of cancer. The venture is based on research done in the laboratory of Vanderbilt chemist Stephen W. Fesik. The partners previously identified compounds that bind . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society